Expert Interviews

Dr Laura Periman introduces current and upcoming pharmacological treatment options, including nasal varenicline, for patients with dry eye disease.

Various treatments for dry eye disease are navigated with regard to both payer and provider considerations.

Dr Periman addresses cost-related concerns associated with treating dry eye disease.

Quality-of-life concerns, including biopsychosocial impacts caused by dry eye disease, are explored by Dr Periman.

Dr Laura Periman, MD illustrates the current risk factors and prevalence regarding patients with dry eye disease.

Dr Bhatia concludes our discussion by outlining what factors physicians should be cognizant of when prescribing therapies to patients with AD.

A dermatology expert highlights the role JAK inhibitors play in AD therapy, from mechanism of action to ruxolitinib and the TrUE AD1 and -2 trials.

Dr Neal Bhatia explains the available treatment options for patients with AD, including their relation to guideline recommendations.

Neal Bhatia, MD, provides an overview of atopic dermatitis (AD) and the diagnostic process, as well as how its severity impacts the patient.

Drs Al-Hendy and Lopes conclude with final thoughts on GnRH receptor antagonists, relugolix and elagolix, changing the UF treatment landscape.

Dr Al-Hendy discusses what it takes to individualize UF treatment for each patient.

Ryan Urgo, Managing Director, Health Policy at Avalere addressed the Biden administration’s healthcare priorities and if the Build Back Better legislation will include provisions that deal with drug prices? Urgo spoke at this year's annual Asembia Specialty Pharmacy Summit in Las Vegas on the subject, as well.

Jayne Hornung, Chief Clinical Officer, Pharmacy, MMIT addresses the difference between digital therapeutics in the pharmacy and medical benefit space, and digs into the potential causes of the slow uptake in digital therapeutics among payers during this year's Asembia Specialty Pharmacy Summit in Las Vegas.

Doug Long, vice president of Industry Relations at IQVIA spoke on how the current inflationary trend in the economy affects healthcare spending and prices, as well as the trend of specialty drugs accounting for half of the drug spend in healthcare. Hear more of what he shared with our team at this year's Asembia Specialty Pharmacy Summit in Las Vegas.

Jayson Slotnik, partner at Health Policy Strategies, Inc, addresses the most recent developments in value-based contracting and how it affects specialty pharmacy at this year's Asembia Specialty Pharmacy Summit in Las Vegas.

Sonia Oskouei, PharmD, vice president of Biosimilars at Cardinal Health, spoke on pharmacists playing a bigger role in driving biosimilar adoption in 2023 and beyond during Asembia's 2022 Specialty Pharmacy Summit in Las Vegas.

Tracy Russell, senior director of state government affairs at CoverMyMeds addressed what piece of new federal legislation will have the biggest effect on specialty pharmacy and what the Biden administration's emphasis on healthcare equity will do for specialty pharmacy. Russell spoke more on this topic at this year's Asembia Specialty Pharmacy Summit in Las Vegas.

Drs Lopes and Al-Hendy describe the unmet needs they see when treating patients with UF.

Dr Maria Lopes provides an overview of common disparities seen when treating and maintaining women’s reproductive health and how these can be minimized.

Carl Schmid concludes with his thoughts on the future of PrEP therapy.

Carl Schmid discusses the opportunities and challenges for use of long-acting PrEP therapy among available treatment options.

Carl Schmid explains the implications of PrEP therapies receiving a Grade A recommendation from the US Preventive Services Task Force.

Dr Lopes discusses the typical payer challenges with managing UF treatment, including pain management.

Dr Al-Hendy highlights the oral GnRH receptor antagonists as first-line therapy for UF.

Carl Schmid describes the steps that can be taken to reduce inequities in PrEP uptake, focusing on community and provider education.

Carl Schmid discusses ideas on how to minimize barriers and increase overall use of PrEP therapy.

Dr Al-Hendy briefly explains how he determines treatment goals during initial workups for patients with UF.

Dr Ayman Al-Hendy details the shift from surgical options to medical therapy for patients with UF.

Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP, elaborates on risk factors for the development of UF.

Maria Lopes, MD, discusses the economic burden of UF from a payer’s perspective, explaining direct and indirect costs associated with the condition.